Diagnosis and treatment of pouchitis

Gastroenterology and Hepatology

Volumn 4, Issue 5, 2008, Pages 355-361

  Shen, Bo ^a   Lashner, Bret A ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Center for Inflammatory Bowel Disease

Author keywords

Ileal pouch; Inflammatory bowel disease; Restorative proctocolectomy

Indexed keywords

ALICAFORSEN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AST 120; BISMUTH CARBONATE; BUDESONIDE; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; GLUTAMINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PROBIOTIC AGENT; RIFAXIMIN; TETRACYCLINE; TINIDAZOLE;

ADENOMATOUS POLYP; CLINICAL TRIAL; COLON RESECTION; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; DYSPLASIA; HUMAN; ILEITIS; INTESTINE ANASTOMOSIS; NEOPLASM; NONHUMAN; PATIENT COMPLIANCE; PROCTOCOLECTOMY; QUALITY OF LIFE; REVIEW; RISK REDUCTION; TREATMENT INDICATION; ULCERATIVE COLITIS;

EID: 44449154257     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Dhillon S, Loftus EV Jr, Tremaine WJ, Jewell DA, Harmsen WS, et al. The natural history of surgery for ulcerative colitis in a population-based cohort from Olmsted County, Minnesota. Am J Gastroenterol. 2005;100:A819.
2. Shen B, Fazio VW, Remzi FH, Delaney CP, Bennett AE, et al. Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouch-anal anastomoses. Am J Gastroenterol. 2005;100:93-101.
3. Penna C, Dozois R, Tremaine W, Sandborn W, LaRusso N, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in parients with associated primary sclerosing cholangitis. Gut. 1996;38:234-239.
4. Fazio VW, Ziv Y, Church JM, Oakley JR, Lavery IC, et al. Ileal pouch-anal anastomosis complications and function in 1005 patients. Ann Surg. 1995;222:120-127.
5. Stocchi L, Pemberton JH. Pouch and pouchitis. Gastroenterol Clin North Am. 2001;30:223-241.
6. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind placebo controlled trial. Gastroenterology. 2003;124:1202-1209.
7. Penna C, Tiret E, Kartheuser A, Hannoun L, Nordlinger B, Parc R. Function of ileal J pouch-anal anastomosis in patients with familial adenomatous polyposis. Br J Surg 1993;80:765-767.
8. Tjandra JJ, Fazio VW, Church JM, Oakley JR, Milsom JW, Lavery IC. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am J Surg. 1993;165:322-325.
9. Duffy M, O'Mahony L, Coffey JC, Collins JK, Shanahan F, et al. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis Colon Rectum. 2002;45:384-388.
10. Nasmyth DG, Godwin PG, Dixon MF, Williams NS, Johnston D. Ileal ecology after pouch-anal anastomosis or ileostomy. Gastroenterology. 1989;96:817-824.
11. Komanduri S, Gillevet PM, Sikaroodi M, Mutlu E, Keshavarzian A. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol. 2007;5:352-360.
12. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology. 1994;107:1856-1860.
13. Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruselervan Embden JG. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum. 2004;47:876-884.
14. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305-309.
15. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-114.
16. Kroesen AJ, Leistenschneider P, Lehmann K, Ransco C, Dullat S, et al. Increased bacterial permeation in long-lasting ileoanal pouches. Inflamm Bowel Dis. 2006;12:736-744.
17. de Silva HJ, Jones M, Prince C, Kettlewell M, Morrensen NJ, Jewell DP. Lymphocyte and macrophage subpopulations in pelvic ileal reservoirs. Gut. 1991;32:1160-1165.
18. Hirata I, Berrebi G, Austin LL, Keren DF, Dobbins WO 3rd. Immunohistological characterization of intraepithelial and lamina propria lymphocytes in control ileum and colon and inflammatory bowel disease. Dig Dis Sci. 1986;31:593-603.
19. Stallmach A, Schafer F, Hoffman S, Weber S, Müller-Molaian I, et al. Increased state of activation of CD4 positive T cells and elevated interferon gamma production in pouchitis. Gut. 1998;43:499-505.
20. Thomas PD, Forbes A, Nicholls RJ, Ciclitira P. Altered expression of the lymphocyte activation markers CD30 and CD27 in patients with pouchitis. Scand J Gastroenterol. 2001;36:258-264.
21. Goldberg PA, Herbst F, Beckett CG, Martelli B, Kontakou M, et al. Leukocyte typing, cytokine expression and epithelial turnover in the ileal pouch in patients with ulcerative colitis and familial adenomatous polyposis. Gut. 1996;38:549-553.
22. Patel RT, Bain I, Youngs D, Keighley MR. Cytokine production in pouchitis is similar to that in ulcerative colitis. Dis Colon Rectum. 1995;38:831-837.
23. Schmidt C, Giese T, Ludwig B, Menges M, Schilling M, et al. Increased cytokine transcripts in pouchitis reflect the degree of inflammation but not the underlying entity. Int J Colorectal Dis. 2006;21:419-426.
24. Gionchetti P, Campieri M, Belluzzi A, Bertinelli E, Ferretti M, et al. Mucosal concentrations of interleukin-1α, interleukin-6, interleukin-8, and tumor necrosis factor-α in pelvic ileal pouches. Dig Dis Sci. 1994;39:1525-1531.
25. Bulois P, Tremaine WJ, Maunoury V, Gambiez L, Hafraoui S, et al. Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. Inflamm Bowel Dis. 2000;6:157-164.
26. Patel RT, Pall AA, Adu D, Keighley MR. Circulating soluble adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1995;7:1037-1041.
27. Chaussade S, Denizot Y, Valleur P, Nicoli J, Raibaud P, et al. Presence of PAF-acether in stool of patients with pouch ileoanal anastomosis and pouchitis. Gastroenterology. 1991;100:419-423.
28. Gertner DJ, Rampton DS, Madden MV, Talbot IC, Nicholls RJ, Lennard-Jones JE. Increased leukotriene B4 release from ileal pouch mucosa in ulcerative colitis compared with familial adenomatous polyposis. Gut. 1994;35:1429-1432.
29. Stucchi AF, Shebani KO, Leeman SE, Wang CC, Reed KL, et al. A neurokinin 1 receptor antagonist reduces an ongoing ileal pouch inflammation and the response to a subsequent inflammatory stimulus. Am J Physiol Gastrointest Liver Physiol. 2003;285:G1259-1267.
30. Stallmach A, Chan CC, Ecker KW, Feifel G, Herbst H, et al. Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut. 2000;47:415-422.
31. Ulisse S, Gionchetti P, D'Alo S, Russo FP, Pesce I, et al. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol. 2001;96:2691-2699.
32. Thomas PD, Forbes A, Nicholls RJ, Ciclitira PJ. Increased mucosal IFN-γ production in pouchitis despite normal functional responses of isolated CD4 cells. Gut. 1999;44(suppl 4):32A.
33. Carter MJ, Di Giovine FS, Cox A, Goodfellow P, Jones S, et al. The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology. 2001;121;805-811.
34. Brett PM, Yasuda N, Yiannakou JY, Herbst F, Ellis HJ, et al. Genetic and immunological markers in pouchitis. Eur J Gastroenterol Hepatol. 1996;8:951-955.
35. Aisenberg J, Legnani PE, Nilubol N, Cobrin GM, Ellozy SH, et al. Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am J Gastroenterol. 2004;99:432-441.
36. Meier C, Hegazi RA, Aisenberg J, Legnani PE, Nilubol N, et al. Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor? Inflamm Bowel Dis. 2005;11:965-971.
37. Schmidt CM, Lazenby AJ, Hendrickson RJ, Sitzmann JV. Preoperative terminal ileal and colonic resection histopathology predicts risk of pouchitis in patients after ileoanal pull-through procedure. Ann Surg. 1998;227:654-662.
38. Achkar JP, Al-Haddad M, Lashner B, Remzi FH, Brzezinski A, et al. Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol. 2005;3:60-66.
39. Okon A, Dubinsky M, Vasiliauskas EA, Papadakis KA, Ippoliti A, et al. Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitis. Am Surg. 2005;71:821-826.
40. Shepherd NA, Hulten L, Tytgat GN, Nicholls RJ, Nasmyth DG, et al. Pouchitis. Int J Colorectal Dis. 1989;4:205-229.
41. Hata K, Watanabe T, Shinozaki M, Nagawa H. Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. Scand J Gastroenterol. 2003;38:1055-1058.
42. Fleshner PR, Vasiliauskas EA, Kam LY, Fleshner NE, Gaiennie J, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut. 2001;49:671-677.
43. Kuisma J, Jarvinen H, Kahri A, Farkkilla M. Factors associated with disease activity of pouchitis after surgery for ulcerative colitis. Scand J Gastroenterol. 2004;39:544-548.
44. Shen B, Fazio VW, Remzi FH, Brzezinski A, Bennett AE, et al. Risk factors for diseases of ileal pouch-anal anastomosis in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:81-89.
45. Hui T, Landers C, Vasiliauskas E, Abreu M, Dubinsky M, et al. Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Dis Colon Rectum. 2005;48:1254-1262.
46. Abdelrazeq AS, Kandiyil N, Botterill ID, Lund JN, Reynolds JR, et al. Predictors for acute and chronic pouchitis following restorative proctocolectomy for ulcerative colitis. Colorectal Dis. 2007 Nov 12; [Epub ahead of print].
47. Pastrana RJ, Torres EA, Arroyo JM, Rivera CE, Sánchez CJ, Morales L. Iron-deficiency anemia as presentation of pouchitis. J Clin Gastroenterol. 2007;41:41-44.
48. Oikonomou IK, Fazio VW, Remzi FH, Lopez R, Lashner BA, Shen B. Risk factors for anemia in patients with ileal pouch-anal anastomosis. Dis Colon Rectum. 2007;50:69-74.
49. Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, et al. Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology. 2001;121:261-267.
50. Moskowitz RL, Shepherd NA, Nicholls RJ. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. Int J Colorectal Dis. 1986;1:167-174.
51. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc. 1994;69:409-415.
52. Nadgir RN, Soto JA, Dendrinos K, Lucey BC, Becker JM, Farraye FA. MRI of complicated pouchitis. AJR Am J Roentgenol. 2006;187:W386-391.
53. Calabrese C, Fabbri A, Gionchetti P, Rizzello F, Morselli C, et al. Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis. Aliment Pharmacol Ther. 2007;25:1311-1316.
54. Shen B, Remzi FH, Santisi J, Lashner BA, Brzezinski A, Fazio VW. Application of wireless capsule endoscopy for the evaluation of iron deficiency anemia in patients with ileal pouches. J Clin Gastroenterol. 2008 Mar 19 [Epub ahead of print].
55. Sandborn WJ. Pouchitis: Risk factors, frequency, natural history, classification and public health prospective. In: McLeod RS, Martin F, Sutherland LR, Wallace JL, Williams CN, eds. Trends in Inflammatory Bowel Disease 1996. Lancaster, UK: Kluwer Academic Publishers; 1997:51-63.
56. Shen B. Diagnosis and management of patients with pouchitis. Drugs. 2003;65:453-461.
57. Mann SD, Pitt J, Springall RG, Thillainayagam AV. Clostridium difficile infection - an unusual cause of refractory pouchitis: report of a case. Dis Colon Rectum. 2003;46:267-270.
58. Shen B, Goldblum JR, Hull TL, Remzi FH, Bennett AE, Fazio VW. Clostridium difficile-associated pouchitis. Dig Dis Sci. 2006;51:2361-2364.
59. Munoz-Juarez M, Pemberton JH, Sandborn WJ, Tremaine WJ, Dozois RR. Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis: report of two cases. Dis Colon Rectum. 1999;42:117-120.
60. Moonka D, Furth EE, MacDermott RP, Lichtenstein GR. Pouchitis associated with primary cytomegalovirus infection. Am J Gastroenterol. 1998;93:264-266.
61. Shen B, Fazio VW, Remzi FH, Bennett AE, Lopez R, et al. Effect of withdrawal of nonsteroidal anti-inflammatory drug use on ileal pouch disorders. Dig Dis Sci. 2007;52:3321-3328.
62. Casadesus D, Tani T, Wakai T, Maruyama S, Iiai T, et al. Possible role of human cytomegalovirus in pouchitis after proctocolectomy with ileal pouch-anal anastomosis in patients with ulcerative colitis. World J Gastroenterol. 2007;13:1085-1089.
63. Stahlberg D, Gullberg K, Liljeqvist L, Hellers G, Lofberg R. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum. 1996;39:1012-1018.
64. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci. 1994;39:1193-1196.
65. Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, et al. A randomized trial of ciprofloxacin and metronidazole in treating acute pouchitis. Inflamm Bowel Dis. 2001;7:301-305.
66. Isaacs KL, Sandler RS, Abreu M, Picco MF, Hanauer SB, et al; Crohn's and Colitis Foundation of America Clinical Alliance. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007;13:1250-1255.
67. Sambuelli A, Boerr L, Negreira S, Gil A, Camartino G, et al. Budesonide enema in pouchitis - a double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther. 2002;16:27-34.
68. Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther. 2004;19:281-286.
69. Shen B, Pardi DS, Bennett AE, Sherman KK. A pilot study of the efficacy and tolerability of AST-120 in the treatment of active pouchitis. Am J Gastroenterol. 2007;102:A979.
70. Shen B, Brzezinski A, Fazio VW, Remzi FH, Achkar JP, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: expetience in clinical practice. Aliment Pharmacol Ther. 2005;22:721-728.
71. Gionchetti P, Rizzello F, Morselli C, Poggioli G, Tambasco R, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum. 2007;50:2075-2082.
72. Schaus BJ, Fazio VW, Remzi FH, Bennett AE, Lashner BA, Shen B. Large polyps in the ileal pouch in patients with underlying ulcerative colitis. Dis Colon Rectum. 2006;50:832-838.
73. Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, et al. Antibiotic combination therapy in patients with chronic treatment-resistant pouchitis. Aliment Pharmacol Ther. 1999;13:713-718.
74. Abdelrazeq AS, Kelly SM, Lund JN, Leveson SH. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis. 2005;7:182-186.
75. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther. 2002;16:909-917.
76. Shen B, Fazio VW, Remzi FH, Bennett AE, Lopez R, et al. Combined ciprofloxacin and tinidazole in the treatment of chronic refractory pouchitis. Dis Colon Rectum. 2007;50:498-508.
77. Viscido A, Kohn A, Papi C, Caprilli R. Management of refractory fistulizing pouchitis with infliximab. Eur Rev Med Pharmacol Sci. 2004;8:239-246.
78. Kühbacher T, Ott SJ, Helwig U, Mimura T, Rizzello F, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut. 2006;55:833-841.
79. Gionchetti P, Rizzello F, Poggioli G, Pierangeli F, Laureti S, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther. 2007;25:1231-1236.
80. Lohmuller JL, Pemberton JH, Dozois RR, Ilstrup D, van Heerden J. Pouchiris and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg. 1990;211:622-629.
81. Mowschenson PM, Critchlow JF, Peppercorn MA. Ileoanal pouch operation: long-term outcome with or without diverting ileostomy. Arch Surg. 2000;135:463-465.
82. Hurst RD, Chung TP, Rubin M, Michelassi F. The implications of acute pouchitis on the long-term functional results after restorative proctocolectomy. Inflamm Bowel Dis. 1998;4:280-284.
83. Madiba TE, Bartolo DC. Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. J R Coll Surg Edinb. 2001;46:334-337.
84. Zins BJ, Sandborn WJ, Penna CR, Landers CJ, Targan SR, et al. Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. Am J Gastroenterol. 1995;90:2177-2180.
85. Freeman K, Shao Z, Remzi FH, Lopez R, Fazio VW, Shen B. Impact of orthotopic liver transplant for primary sclerosing cholangitis on chronic antibiotic refractory pouchitis. Clin Gastroenterol Hepatol. 2008;6:62-68.
86. Das P, Johnson MW, Tekkis PP, Nicholls RJ. Risk of dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis. Colorectal Dis. 2007;9:15-27.
87. Thompson-Fawcett MW, Marcus V, Redston M, Cohen Z, McLeod RS. Risk of dysplasia in long-term ileal pouches and pouches with chronic pouchitis. Gastroenterology. 2001;121:275-281.